Issue Date: January 1, 2018
Start-up Jnana eyes transport proteins
Jnana Therapeutics has launched with $50 million in series A funding to discover small molecules that target a family of membrane proteins called solute carriers (SLCs). “Only a handful” of more than 400 SLC proteins have been tapped as drug targets, Jnana CEO Amir Nashat says. SLCs are important for transporting nutrients and drugs across cell membranes; Jnana’s first programs will focus on ones implicated in immuno-oncology, inflammation, and neurological disease. Jnana’s founders include Harvard University chemist Stuart Schreiber.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society